From basic liver immunology to therapeutic opportunities for liver diseases.
作者信息
Feng Dechun, Gao Bin
机构信息
Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892, USA.
出版信息
Cell Mol Immunol. 2021 Jan;18(1):1-3. doi: 10.1038/s41423-020-00607-2. Epub 2020 Dec 18.
Abstract
摘要
相似文献
1
From basic liver immunology to therapeutic opportunities for liver diseases.从基础肝脏免疫学到肝脏疾病的治疗机遇
Cell Mol Immunol. 2021 Jan;18(1):1-3. doi: 10.1038/s41423-020-00607-2. Epub 2020 Dec 18.
2
[Role of dendritic cells in the immunopathogenesis and therapy of liver diseases].[树突状细胞在肝脏疾病免疫发病机制及治疗中的作用]
Nihon Rinsho Meneki Gakkai Kaishi. 2004 Apr;27(2):64-76. doi: 10.2177/jsci.27.64.
3
Immunological tolerance: the liver effect.免疫耐受：肝脏效应。
J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S488-90. doi: 10.1046/j.1440-1746.17.s4.15.x.
4
Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.肝脏稳态中的肝巨噬细胞：多样性、可塑性和治疗机会。
Cell Mol Immunol. 2021 Jan;18(1):45-56. doi: 10.1038/s41423-020-00558-8. Epub 2020 Oct 12.
5
Immunology and the liver.免疫学与肝脏
Hepatology. 1991 May;13(5):977-94.
6
Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases.间充质干细胞的免疫调节功能在人类肝脏疾病治疗中的意义。
Cell Mol Immunol. 2011 Jan;8(1):19-22. doi: 10.1038/cmi.2010.57. Epub 2010 Nov 22.
7
[Prospect of liver immunology: a report from the 59th Annual Meeting of the American Association for the study of liver diseases].[肝脏免疫学展望：来自美国肝病研究协会第59届年会的报告]
Zhonghua Gan Zang Bing Za Zhi. 2009 Mar;17(3):235-7.
8
[Peritoneal dialysis with a suspension of allogeneic liver cells in the treatment of liver insufficiency].[同种异体肝细胞悬液腹腔内注射治疗肝功能不全]
Khirurgiia (Mosk). 1979 Mar(3):41-6.
9
Immunology and liver disease/liver and metabolic syndrome. Preface.免疫学与肝脏疾病/肝脏与代谢综合征。前言。
Dig Dis. 2010;28(1):5-6. doi: 10.1159/000282058. Epub 2010 May 7.
10
Immunology and liver diseases. Proceedings of the Falk Workshop 2009. Liver and metabolic syndrome. Proceedings of the Falk Symposium 171. October 15-18, 2009. Hannover, Germany. Workshop dedicated to the 80th birthday of Karl-Hermann Meyer zum Bueschenfelde.免疫学与肝脏疾病。2009年福克研讨会会议记录。肝脏与代谢综合征。第171届福克研讨会会议记录。2009年10月15日至18日。德国汉诺威。纪念卡尔 - 赫尔曼·迈耶·祖姆·比申费尔德80岁生日的研讨会
Dig Dis. 2010;28(1):5-299. doi: 10.1159/000282058.
引用本文的文献
1
alveolar macrophages accelerate the progression of precancerous atypical adenomatous hyperplasia by promoting the angiogenic function regulated by fatty acid metabolism.肺泡巨噬细胞通过促进由脂肪酸代谢调节的血管生成功能，加速癌前非典型腺瘤样增生的进展。
Elife. 2025 Jul 14;13:RP101731. doi: 10.7554/eLife.101731.
2
Mechanisms of liver fibrosis in metabolic syndrome.代谢综合征中的肝纤维化机制。
eGastroenterology. 2023 Jun;1(1). doi: 10.1136/egastro-2023-100015.
3
Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma.联合 3p-GPC-3 siRNA 治疗与 PD-1 阻断在肝细胞癌中增强抗肿瘤疗效和免疫记忆。
Oncoimmunology. 2022 Jan 2;11(1):2010894. doi: 10.1080/2162402X.2021.2010894. eCollection 2022.
4
Murine CXCR3CXCR6γδT Cells Reside in the Liver and Provide Protection Against HBV Infection.鼠 CXCR3CXCR6γδT 细胞定殖于肝脏并提供针对 HBV 感染的保护。
Front Immunol. 2022 Jan 21;12:757379. doi: 10.3389/fimmu.2021.757379. eCollection 2021.
本文引用的文献
1
Gut microbiome, liver immunology, and liver diseases.肠道微生物组、肝脏免疫学和肝脏疾病。
Cell Mol Immunol. 2021 Jan;18(1):4-17. doi: 10.1038/s41423-020-00592-6. Epub 2020 Dec 14.
2
Immunological mechanisms and therapeutic targets of fatty liver diseases.脂肪性肝病的免疫机制和治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):73-91. doi: 10.1038/s41423-020-00579-3. Epub 2020 Dec 2.
3
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.肝癌的免疫生物学和免疫治疗：聚焦先天和先天样免疫细胞。
Cell Mol Immunol. 2021 Jan;18(1):112-127. doi: 10.1038/s41423-020-00572-w. Epub 2020 Nov 24.
4
Immunopathobiology and therapeutic targets related to cytokines in liver diseases.与肝脏疾病相关细胞因子的免疫病理生物学及治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):18-37. doi: 10.1038/s41423-020-00580-w. Epub 2020 Nov 17.
5
Neutrophils in liver diseases: pathogenesis and therapeutic targets.肝脏疾病中的中性粒细胞：发病机制与治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):38-44. doi: 10.1038/s41423-020-00560-0. Epub 2020 Nov 6.
6
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease.自身免疫性肝病中的抗原呈递、自身抗体产生和治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):92-111. doi: 10.1038/s41423-020-00568-6. Epub 2020 Oct 27.
7
Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer.先天淋巴细胞：肝脏疾病和癌症的发病机制和治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):57-72. doi: 10.1038/s41423-020-00561-z. Epub 2020 Oct 12.
8
Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.肝脏稳态中的肝巨噬细胞：多样性、可塑性和治疗机会。
Cell Mol Immunol. 2021 Jan;18(1):45-56. doi: 10.1038/s41423-020-00558-8. Epub 2020 Oct 12.
9
Clinical Challenges of Immune Checkpoint Inhibitors.免疫检查点抑制剂的临床挑战。
Cancer Cell. 2020 Sep 14;38(3):326-333. doi: 10.1016/j.ccell.2020.07.004. Epub 2020 Aug 3.
10
Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.白细胞介素-22 通过重编程小鼠受损的再生途径改善慢性肝衰竭急性发作。
J Hepatol. 2020 Apr;72(4):736-745. doi: 10.1016/j.jhep.2019.11.013. Epub 2019 Nov 29.
Zotero 插件